# South Korea Biopharmaceuticals Market > South Korea Biopharmaceuticals Market Research Report By Product Type (Monoclonal Antibodies, Recombinant Proteins, Vaccines, Cellular Therapies), By Application (Oncology, Autoimmune Diseases, Infectious Diseases, Cardiovascular Diseases), By End-use (Hospitals, Biotechnology Companies, Pharmaceutical Companies), and By Route of Administration (Intravenous, Subcutaneous, Intramuscular) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 4.21% - **2024:** $ 6.99 Billion - **2025:** $ 7.28 Billion - **2035:** $ 11 Billion - **Key Players:** AbbVie (US), Roche (CH), Amgen (US), Gilead Sciences (US), Bristol-Myers Squibb (US), Johnson & Johnson (US), Novartis (CH), Sanofi (FR), Merck & Co. (US) **Report ID:** MRFR/MED/49167-HCR · **Pages:** 200 · **Author:** Rahul Gotadki & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-korea-biopharmaceuticals-market-50924 --- ## Market Summary ## **South Korea Biopharmaceuticals Market Overview** As per MRFR analysis, the South Korea Biopharmaceuticals Market Size was estimated at 8.38 (USD Billion) in 2023. The South Korea Biopharmaceuticals Market is expected to grow from 8.77 (USD Billion) in 2024 to 15.23 (USD Billion) by 2035. The South Korea Biopharmaceuticals Market CAGR (growth rate) is expected to be around 5.146% during the forecast period (2025 - 2035). ### **Key South Korea Biopharmaceuticals Market Trends Highlighted** A number of variables, such as increased healthcare demands, government backing, and technical improvements, are driving key trends in the South Korean biopharmaceuticals market. Through its "Biopharma Vision 2025" project, the South Korean government has aggressively encouraged biopharmaceutical research with the goal of making the nation a premier biotechnology powerhouse. By improving research and development efforts, this assistance fosters an atmosphere that supports the expansion of biopharmaceutical businesses. Additionally, the need for improved treatments is being driven by the ageing population and the rising prevalence of chronic diseases, which encourages businesses to concentrate on developing new drugs. Furthermore, there are a lot of market potential to investigate, especially in the areas of biosimilars and personalised medicine. South Korean patient care may change as a result of local businesses creating customised treatments that are tailored to each patient's unique profile in response to the growing popularity of targeted therapies. Furthermore, because of their well-established clinical research capabilities and manufacturing procedures, South Korean companies are well-positioned to benefit from the growing global biosimilars industry. Additionally, the government supports industry-academia collaborations, which promote creativity and quicken the creation of novel biopharmaceutical products. Collaborations and partnerships between South Korean research institutes, universities, and biopharmaceutical companies have significantly increased in recent years. These partnerships are crucial for exchanging information, assets, and technology, all of which can hasten the development of novel medicinal products. Additionally, the emergence of digital health technologies, such as big data and artificial intelligence, is changing the way that pharmaceuticals are created, assessed, and marketed in South Korea as well as the way that biopharmaceutical research is carried out. In order to improve clinical trial efficiency and streamline processes, this digital transition is becoming essential. Strong governmental regulations and rising healthcare demands are driving the biopharmaceuticals market in South Korea to grow and innovate dynamically overall. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **South Korea Biopharmaceuticals Market Drivers** #### **Increasing Prevalence of Chronic Diseases** The South Korea [Biopharmaceuticals](../../../reports/biopharmaceuticals-market-8439) is experiencing significant growth due to the rising prevalence of chronic diseases such as cancer and diabetes. Recent data from the Korean National Health Insurance Service indicates a surge in cancer diagnoses, with the number of patients increasing by approximately 21% over the last decade, reflecting a shift towards more complex healthcare requirements that biopharmaceuticals can address effectively. This rising demand has prompted major established organizations like Samsung Biologics and Celltrion to invest heavily in biopharmaceutical Research and Development to meet the needs of this growing patient population. Their efforts not only focus on the creation of innovative therapies but also align with the South Korean government's initiatives to enhance healthcare technologies, further opening avenues for the biopharmaceutical market to thrive. #### **Government Support and Regulatory Framework** The South Korean government has demonstrated a strong commitment to supporting the Biopharmaceutical industry, evidenced by its 'Biopharma 2030 Strategy,' which aims to establish the country as a global leader in biopharmaceuticals. Key initiatives include financial support for Research and Development, regulatory reforms to expedite product approval, and incentives for domestic production. These initiatives are set to attract international biopharmaceutical companies, which can enhance local manufacturing capabilities and stimulate economic growth. The Ministry of Food and Drug Safety is actively engaged in creating a more favorable regulatory environment, assuring a bright future for the South Korea Biopharmaceuticals Market. #### **Growing Investment in Biotechnology** There has been a marked increase in investment in biotechnology within South Korea, which directly influences the Biopharmaceuticals Market. Data from the Korean Biotechnology Research and Development Center reveal that biotechnology investment grew by 14% in the last year alone, with substantial contributions from both private and public sectors. This influx of investment is likely to spur innovation and drive the development of novel biopharmaceuticals. Organizations such as LG Chem and Hanmi Pharmaceutical are at the forefront, focusing on innovative therapies that combat unmet medical needs, thus expanding the therapeutic landscape in South Korea. ### **South Korea Biopharmaceuticals Market Segment Insights** #### **Biopharmaceuticals Market Product Type Insights** The South Korea Biopharmaceuticals Market showcases a diverse Product Type segment that primarily comprises Monoclonal Antibodies, Recombinant Proteins, Vaccines, and Cellular Therapies. This segment reveals significant growth and a dynamic landscape shaped by innovative therapies and technological advancements. Monoclonal Antibodies have emerged as a cornerstone of modern treatments, particularly in oncology and autoimmune diseases, thanks to their targeted mechanisms and high specificity. They are increasingly utilized for personalized medicine, enhancing healthcare outcomes in South Korea, where there is a rising focus on customized healthcare solutions. Recombinant Proteins represent another vital aspect of the Product Type segmentation, encompassing therapeutic proteins created using recombinant DNA technology. They play a crucial role in treating various conditions, including hormonal deficiencies and certain cancers. This technology facilitates the development of biologics that are vital in treating chronic illnesses, contributing positively to the overall healthcare expenditure in South Korea. Vaccines continue to be a major component of the biopharmaceutical landscape, particularly highlighted by recent global health challenges. South Korea is recognized for its robust vaccination programs, which are paramount for infectious disease prevention. The emphasis on vaccine development enhances public health strategies, reflecting strong government support and investment in Research and Development to foster innovative vaccine solutions. Cellular Therapies are gaining traction as a transformative approach in treating various conditions, including genetic disorders and cancers. These therapies harness the body’s own cells to promote healing and recovery, making them a significant area of interest within the biopharmaceutical sector. The rising demand for cellular therapies reflects a broader trend towards biologics, supporting the healthcare advancements desired in South Korea. The importance of these various Product Types not only underscores the segmentation within the South Korea Biopharmaceuticals Market but also illustrates the alignment of local healthcare priorities with global trends in biopharmaceutical research and application. Each of these segments contributes distinctly to the landscape of healthcare solutions, catering to the increasing demand for effective therapies in a rapidly evolving biopharmaceutical industry. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review #### **Biopharmaceuticals Market Application Insights** The South Korea Biopharmaceuticals Market is experiencing significant growth, particularly within the Application segment, as the country focuses on advancing healthcare solutions. The presence of a robust healthcare infrastructure and favorable government policies supports the development of various therapeutic areas. Oncology remains a critical focus due to the rising incidence of cancer, driving innovations in targeted therapies and immunotherapies. Autoimmune Diseases are also gaining attention, as medications aimed at managing these chronic conditions are necessary for improving patients' quality of life. Infectious Diseases continue to present challenges, especially highlighted by recent global health crises, underscoring the need for effective treatment options and rapid development of vaccines. Cardiovascular Diseases represent a significant health concern, prompting increased investment and research into biopharmaceutical interventions that can enhance patient outcomes. Overall, the South Korea Biopharmaceuticals Market segmentation reveals a dynamic landscape, driven by the urgency of healthcare needs and advancements in biopharmaceutical technologies, ensuring the country remains proactive in addressing diverse medical challenges. #### **Biopharmaceuticals Market End-use Insights** The South Korea Biopharmaceuticals Market, particularly in the End-use segment, showcases a diverse landscape driven by the increasing demand for advanced therapies and treatments across various healthcare settings. Hospitals serve as a crucial end-use category, reflecting a significant reliance on biopharmaceuticals for patient care, including personalized medicine and specialized therapies. With rising patient populations suffering from chronic and complex diseases, the role of biotechnology companies has also grown, as they focus on innovative drug development and cutting-edge research that align with the government's push for biotechnology advancement in healthcare. Additionally, pharmaceutical companies continue to dominate by integrating biopharmaceuticals into their portfolios, responding to market needs for efficacy and safety in treatments. The South Korea biopharmaceutical landscape benefits from strong government support, alongside an increasing focus on Research and Development initiatives, all of which fosters an environment ripe for growth within these segments. As health awareness and medical innovations accelerate, the South Korea Biopharmaceuticals Market remains a pivotal sector with ample opportunities and challenges, bolstered by the ongoing evolution of healthcare needs. #### **Biopharmaceuticals Market Route of Administration Insights** The Route of Administration segment within the South Korea Biopharmaceuticals Market has gained significant attention due to its crucial role in drug delivery methods. This market includes various approaches like Intravenous, Subcutaneous, and Intramuscular administration. Intravenous administration is favored for its rapid onset of action, making it effectively utilized for critical conditions requiring immediate treatment. On the other hand, Subcutaneous administration has seen increased adoption for self-administration, benefiting patients with chronic conditions and aligning with South Korea’s focus on patient-centered healthcare solutions. Intramuscular administration remains vital for vaccines and hormonal therapies, making it a significant component of preventive healthcare strategies in South Korea. The growing prevalence of chronic diseases, along with an aging population, is driving the demand for these administration routes. As the South Korea Biopharmaceuticals Market continues to expand, innovations in drug formulation and delivery methods will likely enhance these routes' efficiency and patient compliance. Rising investments in Research and Development also present opportunities for advancements in the field, contributing to improved treatment outcomes and further strengthening the market landscape. ### **South Korea Biopharmaceuticals Market Key Players and Competitive Insights** The South Korea Biopharmaceuticals Market is characterized by rapid advancements and a robust competitive landscape that has significantly evolved over the past few years. This market is driven by a combination of innovation, strong research and development capabilities, and increasing domestic and international investments. The country's favorable regulatory environment, coupled with a high prevalence of chronic diseases, has underscored the importance of biopharmaceuticals as a pivotal component in the healthcare system. As a result, companies operating in this sphere are increasingly focusing on developing biologics and biosimilars, which are expected to capture a substantial portion of the market share in the coming years. Additionally, strategic partnerships, mergers, and acquisitions are common as firms seek to enhance their product portfolios and expand their market reach. Green Cross Corporation is a prominent player within the South Korea Biopharmaceuticals Market, recognized for its strong presence in the vaccine and plasma-derived products sectors. The company utilizes cutting-edge technology and extensive research capabilities to produce high-quality biopharmaceuticals, positioning itself as a leader in the field. Green Cross Corporation has established a significant market share in the therapeutic protein and vaccine markets, owing to its commitment to quality and innovation. Its strong manufacturing infrastructure and continuous investment in R&D enable the company to address various therapeutic areas, particularly in immunology and infectious diseases. This strategic focus has not only solidified its position in South Korea but has also poised the company to capture opportunities in international markets. Pharmbio is another key contributor to the South Korea Biopharmaceuticals Market, particularly noted for its innovative therapeutic agents and investments in biopharmaceutical contract manufacturing. The company specializes in producing biosimilars and advanced therapeutics, thereby catering to a range of medical conditions that require advanced treatment options. Pharmbio's commitment to quality and compliance has earned it a strong reputation within the sector. Additionally, its strategic collaborations with research institutions and other pharmaceutical entities have facilitated the development of a robust product pipeline. The company is advancing its capabilities through various mergers and acquisitions, thereby strengthening its market presence and enhancing its competitive edge in the ever-evolving landscape of South Korea's biopharmaceuticals sector. Key services include contract development and manufacturing, which appeal to both domestic and international customers seeking reliable biopharmaceutical solutions. #### **Key Companies in the South Korea Biopharmaceuticals Market Include** ### **South Korea Biopharmaceuticals Market Developments** Recent developments in the South Korea Biopharmaceuticals Market reveal significant activity and advancements within the sector. Samsung Biologics reported an expansion in its production capacity as of September 2023, aiming to address the increasing global demand for biopharmaceuticals. In August 2023, Daewoong Pharmaceutical launched a new bio-innovation platform aimed at accelerating drug development processes. Green Cross Corporation announced in July 2023 its collaboration with Generium to develop monoclonal antibodies targeted at autoimmune diseases. Furthermore, the market witnessed substantial growth, with forecasts indicating that by 2025, the South Korean biopharmaceuticals industry could reach an estimated valuation of USD 25 billion, driven by strong investments in Research and Development among key players such as Celltrion, LG Chem, and SK Bioscience. Recent mergers, including the acquisition of Ildong Pharmaceutical by Hanmi Pharmaceutical in June 2023, highlight an ongoing trend toward consolidation in the market. In the last few years, regulatory approvals have also accelerated, with significant milestones achieved for biotech products, enhancing the overall competitiveness of South Korea as a leading biopharmaceutical hub in Asia. ### **South Korea Biopharmaceuticals Market Segmentation Insights** #### **Biopharmaceuticals Market Product Type Outlook** #### **Biopharmaceuticals Market Application Outlook** #### **Biopharmaceuticals Market End-use Outlook** #### **Biopharmaceuticals Market Route of Administration Outlook** ## Market Drivers ### Rising Focus on Biosimilars The biopharmaceuticals market in South Korea is witnessing a rising focus on biosimilars, which are biologic medical products highly similar to already approved reference products. The increasing cost of biologic therapies has prompted healthcare providers to seek more affordable alternatives, thereby driving the demand for biosimilars. By 2025, the biosimilars segment is expected to account for approximately 25% of the total biopharmaceuticals market revenue. This shift not only enhances patient access to essential medications but also fosters competition among manufacturers, potentially leading to lower prices. As regulatory pathways for biosimilars become more streamlined, the market is likely to see an influx of new products, further bolstering growth. ### Government Support and Funding Initiatives The South Korean government is actively supporting the biopharmaceuticals market through various funding initiatives and policy frameworks. In recent years, substantial investments have been made to foster innovation and research in biotechnology. The government aims to increase the biopharmaceuticals market's contribution to the national economy, targeting a growth rate of 10% annually. Initiatives such as tax incentives for R&D and grants for startups are designed to stimulate growth and attract foreign investment. This supportive environment is likely to enhance the overall competitiveness of the biopharmaceuticals market, encouraging both domestic and international players to invest in South Korea. ### Increasing Demand for Innovative Therapies The biopharmaceuticals market in South Korea is experiencing a notable surge in demand for innovative therapies. This trend is driven by a growing prevalence of chronic diseases and an aging population, which necessitates advanced treatment options. In 2025, the market is projected to reach approximately $10 billion, reflecting a compound annual growth rate (CAGR) of around 8%. The increasing focus on research and development within the biopharmaceutical sector is likely to yield novel therapies that address unmet medical needs. As healthcare providers and patients alike seek more effective treatment modalities, the biopharmaceuticals market is poised for substantial growth, driven by the introduction of cutting-edge therapies that enhance patient outcomes. ### Collaboration Between Academia and Industry Collaboration between academic institutions and the biopharmaceuticals market is becoming increasingly prevalent in South Korea. These partnerships facilitate the translation of research findings into practical applications, accelerating the development of new therapies. Universities and research institutes are often at the forefront of biopharmaceutical innovation, providing valuable insights and expertise. In 2025, it is anticipated that collaborative projects will contribute to over 20% of the new product pipeline in the biopharmaceuticals market. This synergy not only enhances the research capabilities of companies but also fosters a culture of innovation, positioning South Korea as a leader in biopharmaceutical research and development. ### Advancements in Biomanufacturing Technologies Technological advancements in biomanufacturing are significantly impacting the biopharmaceuticals market in South Korea. Innovations such as continuous manufacturing and single-use technologies are streamlining production processes, thereby reducing costs and improving efficiency. These advancements enable companies to scale up production while maintaining high-quality standards. In 2025, it is estimated that biomanufacturing technologies will account for over 30% of the total production capacity in the biopharmaceuticals market. This shift not only enhances the competitiveness of South Korean firms but also positions them favorably in the international market. As these technologies evolve, they are expected to facilitate the rapid development and commercialization of new biopharmaceutical products. ## Future Outlook The [Biopharmaceuticals Market](https://www.marketresearchfuture.com/reports/biopharmaceuticals-market-8439) in South Korea is projected to grow at a 4.21% CAGR from 2025 to 2035, driven by innovation, regulatory support, and increasing healthcare demands. **New opportunities:** - Investment in personalized medicine development Expansion of biosimilars portfolio for cost-effective treatments Partnerships with tech firms for digital health solutions By 2035, the market is expected to achieve robust growth, positioning itself as a leader in biopharmaceutical innovation. ## Segment Insights ### By Product Type: Monoclonal Antibodies (Largest) vs. Cellular Therapies (Fastest-Growing) In the South Korea biopharmaceuticals market, Monoclonal Antibodies dominate the product type segment, capturing a significant share due to their widespread use in treating various diseases, including cancers and autoimmune disorders. This segment benefits from ongoing research and development efforts, which continue to enhance the efficacy and safety profiles of these therapeutics. Meanwhile, Recombinant Proteins and Vaccines follow, showcasing their essential roles in therapeutic interventions and preventive medicine, respectively. Growth trends in the South Korea biopharmaceuticals market indicate that Cellular Therapies are rapidly gaining traction, driven by innovations and increased investments in regenerative medicine. The demand for personalized treatment options fosters the expansion of this segment, while regulatory support and technological advancements also contribute to its evolution. Meanwhile, the Monoclonal Antibodies segment remains robust, continuing to be a cornerstone of biopharmaceutical therapies as they expand into new indications and enhance treatment outcomes. Monoclonal Antibodies (Dominant) vs. Cellular Therapies (Emerging) Monoclonal Antibodies are characterized by their specificity and ability to target particular antigens, making them a key player in the therapeutic landscape. This product type has established a strong market presence due to its effectiveness in treating chronic illnesses and its integration into treatment protocols. Conversely, Cellular Therapies represent an emerging frontier, offering potential cures through advanced techniques that leverage the body’s own cells. Their innovative approaches, including stem cell therapies and gene editing, are poised to transform treatment paradigms, thus attracting considerable attention from researchers and investors alike as advancements continue to unfold. ### By Application: Oncology (Largest) vs. Autoimmune Diseases (Fastest-Growing) In the South Korea biopharmaceuticals market, oncology holds a significant market share, dominating the application segment due to a rising prevalence of cancer and an increasing focus on novel therapeutics. Autoimmune diseases follow closely behind, showcasing a robust market share as healthcare advancements facilitate better diagnosis and treatment options. The growth trends within the South Korea biopharmaceuticals market are largely driven by ongoing research and development in oncology, aimed at innovative biologic and targeted therapies. Additionally, the autoimmune diseases sector is witnessing rapid growth fueled by awareness campaigns and an aging population. Investment in cutting-edge drug discovery methods also supports the expansion of these segments, reflecting a dynamic shift in healthcare priorities. Oncology (Dominant) vs. Autoimmune Diseases (Emerging) Oncology remains the dominant application in the South Korea biopharmaceuticals market, characterized by advanced therapeutic options such as monoclonal antibodies and CAR T-cell therapies that have revolutionized patient care. This dominance is supported by substantial investment and governmental initiatives promoting cancer research. Conversely, the autoimmune diseases sector is an emerging area, distinguished by innovations in treatment modalities, including biologics that target specific pathways. Both segments are pivotal, with oncology addressing critical health challenges, while autoimmune diseases represent a growing market opportunity, poised for significant advancements as new therapies gain regulatory approval. ### By End-use: Hospitals (Largest) vs. Biotechnology Companies (Fastest-Growing) In the South Korea biopharmaceuticals market, hospitals comprise the largest share of the end-use segment, significantly influencing market dynamics. This sector captivates attention due to its essential role in patient care and the demand for innovative therapies. Meanwhile, biotechnology companies are emerging rapidly as pivotal players, capturing a growing market share as they introduce cutting-edge technologies and therapies into the healthcare system. Growth trends indicate that while hospitals remain dominant in terms of acquisition and distribution of biopharmaceutical products, biotechnology companies are witnessing the fastest growth due to increased R&D activities and strategic partnerships. The drive for personalized medicine and biopharmaceutical innovations is strengthening the position of biotechnology firms, making them crucial contributors to the market's overall expansion. Hospitals (Dominant) vs. Biotechnology Companies (Emerging) Hospitals serve as the dominant end-user in the South Korea biopharmaceuticals market, benefiting from their critical role in treating patients with complex health issues using advanced therapy products. Hospitals invest heavily in biopharmaceuticals to improve patient outcomes and streamline operations. Conversely, biotechnology companies represent an emerging force in this sector, leveraging advancements in genetic research and biomanufacturing. Their ability to develop novel therapies positions them as agile innovators, capable of rapidly responding to market needs. The collaboration between hospitals and biotechnology firms fosters a dynamic ecosystem, enhancing the overall efficacy of biopharmaceuticals in the healthcare landscape. ### By Route of Administration: Intravenous (Largest) vs. Subcutaneous (Fastest-Growing) In the South Korea biopharmaceuticals market, the route of administration segment is notably influenced by intravenous, subcutaneous, and intramuscular methods. Among these, intravenous administration stands out as the largest segment, primarily due to its widespread application in hospital settings where immediate drug efficacy is crucial. Subcutaneous administration is also gaining traction, contributing steadily to the market share through its advantages in ease of use and self-administration, making it increasingly favored by patients and healthcare professionals alike. Looking at growth trends, subcutaneous administration is recognized as the fastest-growing method, driven by technological advancements in device design that enhance patient comfort and compliance. Additionally, the rising preference for outpatient care and home-based treatments further propels the adoption of subcutaneous injections. Meanwhile, intravenous methods continue to thrive in specialized clinical environments, with innovations aimed at improving safety and efficacy fueling their sustained relevance in therapeutic applications. Intravenous (Dominant) vs. Subcutaneous (Emerging) The intravenous route of administration remains the dominant force in the South Korea biopharmaceuticals market, primarily owing to its critical role in acute care and the treatment of severe diseases. This method ensures rapid drug delivery, which is paramount for high-potency biologics typically used in oncology and critical care. On the other hand, subcutaneous administration is emerging as a vital alternative, particularly in the management of chronic conditions such as diabetes and rheumatoid arthritis, where patient convenience and adherence are essential. The growing availability of prefilled syringes and wearable injectors enhances the appeal of subcutaneous delivery, positioning it as a key player for the future. ## Competitive Benchmarking The biopharmaceuticals market in South Korea is characterized by a dynamic competitive landscape, driven by innovation, regulatory support, and increasing healthcare demands. Major players such as AbbVie (US), Roche (CH), and Amgen (US) are strategically positioned to leverage their extensive research capabilities and established market presence. AbbVie (US) focuses on immunology and oncology, emphasizing the development of novel therapies, while Roche (CH) is heavily invested in personalized medicine and diagnostics. Amgen (US) continues to expand its biosimilars portfolio, indicating a shift towards more cost-effective treatment options. Collectively, these strategies foster a competitive environment that prioritizes innovation and patient-centric solutions.Key business tactics within the market include localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness. The competitive structure appears moderately fragmented, with several key players exerting influence over various therapeutic areas. This fragmentation allows for niche players to emerge, yet the collective strength of established companies shapes market dynamics significantly. In October AbbVie (US) announced a strategic partnership with a local biotech firm to co-develop a new immunotherapy targeting specific cancer types. This collaboration not only enhances AbbVie's research capabilities but also aligns with South Korea's growing emphasis on personalized medicine, potentially accelerating the development of innovative treatments tailored to local patient needs. In September Roche (CH) launched a new digital health platform aimed at integrating real-time patient data into clinical decision-making processes. This initiative underscores Roche's commitment to digital transformation, enhancing its ability to deliver personalized healthcare solutions while improving patient outcomes. The platform's success could redefine how biopharmaceutical companies engage with healthcare providers and patients alike. In August Amgen (US) expanded its biosimilars portfolio by acquiring a local manufacturer specializing in biologics. This acquisition is strategically significant as it not only strengthens Amgen's market position but also reflects a broader trend towards biosimilars in South Korea, where cost containment in healthcare is increasingly prioritized. The move may enhance access to essential therapies for patients while positioning Amgen as a leader in this growing segment. As of November current competitive trends in the biopharmaceuticals market include a pronounced focus on digitalization, sustainability, and the integration of artificial intelligence (AI) in drug development processes. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise to drive innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a model that emphasizes technological advancement, innovative therapies, and robust supply chain reliability. This shift may redefine how companies position themselves in the market, ultimately benefiting patients through improved access to cutting-edge treatments. ## Recent News & Developments Recent developments in the South Korea Biopharmaceuticals Market reveal significant activity and advancements within the sector. Samsung Biologics reported an expansion in its production capacity as of September 2023, aiming to address the increasing global demand for biopharmaceuticals. In August 2023, Daewoong Pharmaceutical launched a new bio-innovation platform aimed at accelerating drug development processes. Green Cross Corporation announced in July 2023 its collaboration with Generium to develop monoclonal antibodies targeted at autoimmune diseases. Furthermore, the market witnessed substantial growth, with forecasts indicating that by 2025, the South Korean biopharmaceuticals industry could reach an estimated valuation of USD 25 billion, driven by strong investments in Research and Development among key players such as Celltrion, LG Chem, and SK Bioscience. Recent mergers, including the acquisition of Ildong Pharmaceutical by Hanmi Pharmaceutical in June 2023, highlight an ongoing trend toward consolidation in the market. In the last few years, regulatory approvals have also accelerated, with significant milestones achieved for biotech products, enhancing the overall competitiveness of South Korea as a leading biopharmaceutical hub in Asia. ## Report Scope | MARKET SIZE 2024 | 6.99(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 7.28(USD Billion) | | MARKET SIZE 2035 | 11.0(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.21% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | AbbVie (US), Roche (CH), Amgen (US), Gilead Sciences (US), Bristol-Myers Squibb (US), Johnson & Johnson (US), Novartis (CH), Sanofi (FR), Merck & Co. (US) | | Segments Covered | Product Type, Application, End-use, Route of Administration | | Key Market Opportunities | Advancements in personalized medicine and biologics drive growth in the biopharmaceuticals market. | | Key Market Dynamics | Rising investment in Research and Development drives innovation in South Korea's biopharmaceuticals market. | | Countries Covered | South Korea | ## Frequently Asked Questions **Q: What was the overall market valuation of the biopharmaceuticals market in 2024?** A: The overall market valuation was $6.99 Billion in 2024. **Q: What is the projected market valuation for the biopharmaceuticals market by 2035?** A: The projected market valuation for 2035 is $11.0 Billion. **Q: What is the expected CAGR for the biopharmaceuticals market during the forecast period 2025 - 2035?** A: The expected CAGR for the biopharmaceuticals market during the forecast period 2025 - 2035 is 4.21%. **Q: Which product type segment had the highest valuation in 2024?** A: The Monoclonal Antibodies segment had the highest valuation at $2.1 Billion in 2024. **Q: What is the projected valuation for the Cellular Therapies segment by 2035?** A: The projected valuation for the Cellular Therapies segment by 2035 is $3.4 Billion. **Q: Which application segment is expected to grow the most by 2035?** A: The Oncology application segment is expected to grow the most, reaching $3.5 Billion by 2035. **Q: What was the valuation of the Biotechnology Companies end-use segment in 2024?** A: The Biotechnology Companies end-use segment was valued at $2.5 Billion in 2024. **Q: What is the projected valuation for the Intravenous route of administration by 2035?** A: The projected valuation for the Intravenous route of administration by 2035 is $4.25 Billion. **Q: Which key players are leading the biopharmaceuticals market?** A: Key players in the market include AbbVie, Roche, Amgen, and Gilead Sciences. **Q: What was the valuation of the Autoimmune Diseases application segment in 2024?** A: The Autoimmune Diseases application segment was valued at $1.5 Billion in 2024. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-korea-biopharmaceuticals-market-50924*